Elicio Therapeutics, Inc. Proceeds from Long-term Lines of Credit
Elicio Therapeutics, Inc. (ELTX) reported Proceeds from Long-term Lines of Credit of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2022-03-30
- Elicio Therapeutics, Inc. proceeds from long-term lines of credit for the quarter ending 2021-12-31 was $0.00.
- Elicio Therapeutics, Inc. proceeds from long-term lines of credit for the quarter ending 2021-09-30 was $0.00.
- Elicio Therapeutics, Inc. proceeds from long-term lines of credit for the quarter ending 2020-12-31 was $0.00.
- Elicio Therapeutics, Inc. proceeds from long-term lines of credit for the quarter ending 2020-09-30 was $0.00.
- Elicio Therapeutics, Inc. proceeds from long-term lines of credit for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Elicio Therapeutics, Inc. proceeds from long-term lines of credit for fiscal 2020 was $895.00K.
| Period end | Proceeds from Long-term Lines of Credit 3 month | Proceeds from Long-term Lines of Credit 6 month | Proceeds from Long-term Lines of Credit 9 month | Proceeds from Long-term Lines of Credit 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $0.00 derived: sum of 2 quarters · filed 2022-03-30 | $0.00 10-K · filed 2022-03-30 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $0.00 derived: sum of 2 quarters · filed 2022-03-30 | $895.00K 10-K · filed 2022-03-30 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $895.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $895.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |